NCT02346461View on ClinicalTrials.gov

An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 5, 2015

Primary Completion Date

December 30, 2017

Study Completion Date

November 15, 2018

Conditions
GNE Myopathy
Interventions
DRUG

ManNAc

At doses of 3 g and 6 g twice daily for a total dose of 6 and 12 g per day.

DRUG

ManNAc

At doses of 6 g twice daily (12 g per day).

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

National Human Genome Research Institute (NHGRI)

NIH

NCT02346461 - An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy | Biotech Hunter | Biotech Hunter